TROP-2-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025: Market Opportunities with High Trop-2 Expression in Multiple Aggressive Cancers Like Breast and Bladder - ResearchAndMarkets.com

The "Pipeline of TROP-2-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.

This competitive intelligence report about TROP-2-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research and development targeting TROP-2. This report will be prepared on demand within one working day upon order placement. The report lists TROP-2-targeted R&D programs by R&D phase in a tabular format and describes in brief the profile of TROP-2-targeted immunotherapies by drug modality.

The transmembrane glycoprotein Trop-2 is highly expressed in many cancers, but not all, and has differential expression in certain normal tissues. Trop-2 is also known as trophoblast antigen 2, cell surface glycoprotein Trop2, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, membrane component chromosome 1 surface marker 1 M1S1, epithelial glycoprotein-1, EGP-1, CAA1, Gelatinous Drop-Like Corneal Dystrophy GDLD, and TTD2. It is coded by the gene Tacstd2. It is about 35 kDa. Trop2 spans the cellular membrane: it has an extracellular, a transmembrane, and an intracellular domain, along with a cytoplasmic tail essential for signaling.

Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and bladder cancers. Trop-2 expression correlates with tumor aggressiveness. Trop-2 overexpression promotes the growth, proliferation, and metastasis of tumor cells.

Two Trop-2 directed antibody-drug conjugates are currently approved and commerciliazed: Trodelvy and Datroway. TRODELVY is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the microenvironment. DATROWAY is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.

Trodelvy is currently approved in more than 50 countries for second-line or later metastatic triple-negative breast cancer (TNBC) patients and in more than 40 countries for certain patients with pre-treated HR+/HER2- metastatic breast cancer. Trodelvy is currently being evaluated in multiple ongoing Phase 3 trials across a range of tumor types with high Trop-2 expression. These studies with Trodelvy, both in monotherapy and in combination with pembrolizumab, involve earlier lines of treatment for TNBC and HR+/HER2- breast cancer - including in curative settings - as well as in lung and gynecologic cancers, where previous proof-of-concept studies have demonstrated clinical activity.

DATROWAY (6 mg/kg) is approved in more than 30 countries worldwide for the treatment of adult patients with unresectable or metastatic HR positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. DATROWAY (6 mg/kg) is approved in Russia and the U.S. for the treatment of adult patients with locally advanced or metastatic EGFR-mutated NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy. Continued approval for this indication in the U.S. may be contingent upon verification and description of clinical benefit in the confirmatory trial.

Trodelvy already became a blockbuster biologic with 2024 sales of US$ 1,315 mln.

The commercial success of Trodelvy and the clinical validation of TROP-2 by Trodelvy and Datroway has attracted many followers applying their proprietary drug modality technologies to generate next generation TROP2-targeted immunotherapy candidates.

For more information about this report visit https://www.researchandmarkets.com/r/2niu21

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251201723146/en/